Perfil clínico y curso evolutivo de los pacientes tratados con efalizumab tras la suspensión de su autorización por la EMEA. Estudio observacional y multicéntrico-Reference-Cited by-同舟云学术

Perfil clínico y curso evolutivo de los pacientes tratados con efalizumab tras la suspensión de su autorización por la EMEA. Estudio observacional y multicéntrico

Published:2011-06 Issue:5 Volume:102 Page:354-364
ISSN:0001-7310
Container-title:Actas Dermo-Sifiliográficas
language:es
Short-container-title:Actas Dermo-Sifiliográficas

Author:

Morell L.,Carrascosa J.M.,Ferrándiz C.,García-Bustinduy M.,Fonseca E.,Carretero G.,Daudén E.,Marrón S.E.,López-Estebaranz J.L.,Ferrán M.,Sánchez-Regaña M.,Muñoz-Santos C.,Belinchón I.,Puig Luis

Publisher

Elsevier BV

Subject

Dermatology,Histology,Pathology and Forensic Medicine

Reference29 articles.

1. Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo.controlled trial;Dubertret;Br J Dermatol,2006

2. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open label extension of a phase IIIb trial;Hamilton;Drug Saf,2008

3. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials;Brimhall;Br J Dermatol,2008

4. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials;Schmitt;Br J Dermatol,2008

5. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials;Zhang;Med Klin,2009

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude;Homeopathy;2016-11